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ABSTRACT 27 
Parachlamydia acanthamoebae and Neochlamydia hartmanellae are Chlamydia-related 28 
bacteria naturally infecting free-living amoebae. These strict intracellular bacteria might 29 
represent emerging pathogens. Recent studies report an association with lower respiratory 30 
tract infections, especially with pneumonia where they have been identified as a potential 31 
causative agent in 1-2% of cases. In this study, we defined the antibiotic susceptibility of 32 
Neochlamydia hartmanellae, two strains of Parachlamydia acanthamoebae and two yet 33 
unclassified Parachlamydiaceae strains using a quantitative approach.  34 
We confirmed the results obtained earlier for P. acanthamoebae strain Bn9 in an 35 
observational study. Macrolides (MICs < 0.06 - 0.5 µg/ml), rifampicin (MICs 0.25-0.5, 1-2 36 
µg/ml) and doxycycline were active against P. acanthamoebae strains and Neochlamydia. All 37 
strains were resistant to amoxicillin, ceftriaxone and imipenem (MIC >32 µg/ml). Similarly to 38 
other Chlamydia-related bacteria, all investigated Parachlamydiaceae were resistant to 39 
quinolones (MICs > 16 µg/ml). Therefore, we recommend a treatment with macrolides for 40 
Parachlamydia-associated pneumonia.  41 
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  44 
INTRODUCTION 45 
In the past few years various Chlamydia-related bacteria, such as Parachlamydia 46 
acanthamoebae and Neochlamydia hartmanellae have been discovered, extending our 47 
knowledge on the Chlamydiales ecology. Similarly to the pathogenic Chlamydia trachomatis 48 
and Chlamydia pneumoniae, these obligate intracellular bacteria are characterized by their 49 
biphasic developmental cycle with infectious elementary bodies (EBs) and replicative 50 
reticulate bodies (RBs). They have been assigned to the Parachlamydiaceae family level-51 
lineage based on highly taxonomic discriminative genes [1,2] and are known to naturally 52 
infect free-living amoebae [3,4]. 53 
Various works suggest a role of P. acanthamoebae as a causative agent of pneumonia and 54 
other lower respiratory tract infections [5]. A first hint was suggested by its isolation from the 55 
water of an humidifier involved in an epidemic of fever in Vermont, USA [6]. This was 56 
further confirmed by a positive association with evidence of acute infections to P. 57 
acanthamoebae and community acquired pneumonia (CAP) [7], ventilator associated 58 
pneumonia (VAP) [8] and nosocomial pneumonia [9]. In addition, P. acanthamoebae DNA 59 
was identified in 2 cases of lower respiratory tract infections in children [10] as well as in 60 
13% of children with bronchiolitis [11]. Similar findings were also shown for other members 61 
of the Parachlamydiaceae, such as Protochlamydia amoebophila [12] and Protochlamydia 62 
naegleriophila [13]. Despite low prevalence of direct isolation of these organisms (less than 63 
1% in CAP and 8% in VAP), cases of Parachlamydiaceae-associated pneumonia were clearly 64 
documented leaving no doubt of the pathogenic role of these species. A low prevalence of 65 
Chlamydia pneumoniae-associated pneumonia was also observed in recent studies [14–16]. 66 
Its clinical relevance is, nonetheless, not debated.  67 
These findings suggest that Parachlamydiaceae might be responsible for at least some cases 68 
of pneumonia of unidentified etiology. Therefore, it is crucial to verify that current 69 
recommended empirical treatments of pneumonia are effective on these emerging pathogens. 70 
Partial information is already given by the work performed by Maurin et al. [17]. However, in 71 
this study, minimal inhibitory concentrations (MICs) were defined as the lowest concentration 72 
that prevented amoebal lysis and therefore provides information based on indirect 73 
observations that might be influenced by additional aspects than bacterial growth [18].  74 
In this work, we used a specific real-time PCR to define quantitatively the antibiotic 75 
susceptibility of Neochlamydia hartmanellae, two strains of P. acanthamoebae and two yet 76 
unclassified Parachlamydiaceae strains. This approach has already been applied to determine 77 
antibiotic susceptibility of other Chlamydia-related bacteria [19,20] and is now considered as 78 
the standard technique to define antibiotic susceptibility. It should therefore be preferentially 79 
used to perform comparisons.  80 
 81 
MATERIAL AND METHODS 82 
Parachlamydia acanthamoebae strain Hall’s coccus, Parachlamydia acanthamoebae strain 83 
BN9 (ATCC VR-1476), Parachlamydia sp. TUMPL1 and the Neochlamydia sp. UWC22 84 
were grown within Acanthamoeba polyphaga strain Linc AP-1 as previously described [21]. 85 
Neochlamydia hartmanellae (symbiont of Hartmanella vermiformis ATCC 50802) was 86 
grown similarly within Hartmanella vermiformis strain BL. After 6 days of incubation, 87 
cultures were harvested and the broth was centrifuged at 180 x g for 10 minutes to eliminate 88 
most amoebae. The supernatant was then diluted at 1:1000 in Page's amoebal saline (PAS) 89 
[21], which corresponds to an approximate final concentration of about 103 bacteria/ml. 50 µl 90 
of this inocolum was then used to infect Acanthamoeba polyphaga strain Linc AP-1 91 
(Parachlamydia and Parachlamydiaceae-related strain) and Hartmanella vermiformis strain 92 
BL (Neochlamydia hartmanellae), respectively, distributed in a 96-wells Costar micro plates 93 
(Corning) at a concentration of 5x105 amoebae/ml. These amoebae were grown axenically as 94 
previously described [21]. After two hours of incubation, at 32°C, to allow internalization, 50 95 
µl of serial antibiotics dilutions were added. Antibiotics tested in this study were doxycycline 96 
[0.06-4 µg/ml] (Pfizer, Neuilly, France), erythromycin [0.06-4 µg/ml] (Abbot, Rungis, 97 
France), clarithromycin [0.06-4 µg/ml] (SmithKline Beecham, Nanterre, France), rifampicin 98 
[0.06-4 µg/ml] (Cassenne, Puteaux, France). Other antibiotics, that were expected to be 99 
ineffective on Parachlamydiaceae based on the work of Maurin et al [17], were tested at a 100 
single high concentration: ofloxacin [16 µg/ml] (Diamant, Puteaux, France), ciprofloxacin [16 101 
µg/ml] (Bayer Pharma, Sebs, France), amoxicillin [100 and 32 µg/ml] (SmithKline Beecham, 102 
Nanter, France), ceftriaxone [100 and 32 µg/ml] (Roche, Paris, France) and imipenem [100 103 
and 32 µg/ml]. Antibiotics were tested in duplicate. 104 
Growth was assessed using a real time TaqMan PCR assay at 2, 24, 48, 72 and 96 hours 105 
post infection. Briefly, bacterial co-cultures were incubated at 32°C and wells were 106 
harvested at the adequate time. DNA was extracted from 200 µl aliquots of infected 107 
amoebal cells using the BioRad Genomic DNA Kit (BioRad Laboratories, Hercules, Ca), 108 
as described by the manufacturer. The extracted nucleic acid was resuspended in a final 109 
volume of 50 µl and stored at -20°C until used in the quantitative PCR assay. 110 
Antibiotic-free wells served as growth controls while uninfected amoebae wells served as 111 
negative controls. The absence of toxicity of antibiotics to amoebal cells was determined 112 
by examining the amoebal micro plates once a day under an inverted microscope (Zeiss 113 
Axiovert 25, Carl Zeiss). To assess the activity and dilution of the antibiotics used, MICs 114 
were determined for Escherichia coli ATCC 8739 and Staphylococcus aureus ATCC 115 
49976 (Institut Pasteur, Marnes La Coquette, France) using Mueller-Hinton agar 116 
(bioMérieux) incubated at 37°C for 18 hours. 117 
Quantitative PCR was performed using TaqMan technology in a final volume of 25 µl 118 
including 12.5 µl of the TaqMan Universal Master Mix (Applied Biosystems, Foster City, Ca) 119 
200 nM of the forward primer (abF 5'- CTCGTGCCGTGAGGTGTT), 200 nM of the reverse 120 
primer (abR 5'- AGCACGTGTGTAGCCCCA), 100 nM of the fluorescent labeled probe (6-121 
FAM-5'-TCAGGTGGGAACTCTAATGAGACTGCCT 3'-TAMRA, where 6-FAM is 6-122 
carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine), 2.5 µl of water and 2.5 123 
µl of DNA. Amplification and detection were performed on the ABI 7900HT sequence 124 
detection system (TaqMan system, Applied Biosystems). Cycling conditions were 2 minutes 125 
at 50°C, 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 126 
60°C. DNA extracted from tittered Parachlamydia and water were used as positive and 127 
negative controls, respectively. The number of bacteria/ml in each sample was then 128 
determined by comparing the threshold cycle (CT) of the sample to that of the tittered positive 129 
control used to establish a calibration curve. 130 
 131 
RESULTS 132 
In this study, we evaluated the susceptibility of various members of the Parachlamydiaceae to 133 
six classes of antibiotics. MICs were defined using a quantitative PCR as the minimal 134 
concentration that prevented bacterial growth. The cut-off used to define a significant 135 
prevention of bacterial growth was the presence of less than a 100 bacterial copies at day 3, 136 
based on the growth kinetics in the absence of antibiotics (figure 1). Both strains of P. 137 
acanthamoebae exhibited a lag in their growth at day 3. Therefore cut-off was adjusted to less 138 
than 10 copies to ensure a better discrimination and growth at day 4 was tested to establish the 139 
susceptibility to ceftriaxone. No antibiotic toxicity was observed on the amoebae (data not 140 
shown). We showed that Parachlamydiaceae were resistant to β-lactams (MIC >32 µg/ml) as 141 
well as to quinolones (MIC >16 µg/ml); such concentrations are, indeed, never achieved in 142 
the human body. As expected, macrolides were active against all species even at a 143 
concentration of 0.06 µg/ml for clarithromycin (MIC <0.06 µg/ml) and 0.06-0.5 µg/ml for 144 
erythromycin. Doxycycline was active against both strains of P. acanthamoebae and 145 
Neochlamydia hartmanellae (MICs 2-4 µg/ml). However, MICs seemed to be higher for the 146 
unclassified Parachlamydiaceae (≥8 µg/ml). Parachlamydiaceae were also susceptible to 147 
rifampicin, with a stronger efficacy against P. acanthamoebae species (MIC 0.25-0.5 µg/ml) 148 
versus Neochlamydia (MIC 2 µg/ml) (figure 2). 149 
 150 
DISCUSSION 151 
In this paper, we confirmed the results obtained for P. acanthamoebae strain BN9 by Maurin 152 
et al. [17] using a reliable quantitative approach and extended these observations to additional 153 
members of the Parachlamydiaceae. We demonstrated that the antibiotic susceptibility of 154 
Parachlamydiaceae in amoebae is quite similar to what is known for other members of the 155 
Chlamydiales (see table 1). Macrolides are the treatment of choice. Cyclines might be an 156 
alternative, at least for P. acanthamoebae strains and Neochlamydia hartmanellae, but 157 
conclusions are difficult to draw due to the in vitro amoeabal model used in our study. Indeed, 158 
it has already been demonstrated that amoebae are a good alternative to mammalian cells lines 159 
to test the antibiotic susceptibility for species that strictly grow in amoebae, as similar results 160 
are obtained in both cell types [20]. However, caution should be taken regarding doxycycline, 161 
which MIC tends to be higher in amoebae due to the likely presence of an efflux pump [20]. 162 
In our study, we found a MIC of 4μg/ml that might be overestimated compared to mammalian 163 
cells. Nevertheless, even if a concentration of 4μg/ml is required to inhibit bacterial growth in 164 
humans, doxycycline is still an acceptable treatment for Parachlamydia-related pneumonia, as 165 
it was shown that such lung concentrations were achieved in humans after a single dose of 166 
200 mg IV doxycycline [22]. Confirmation of our results in a mammalian cell model seems to 167 
be difficult. Indeed, so far, it has not been possible to grow Neochlamydia hartmanellae in 168 
mammalian cells in vitro and, even if P. acanthamoebae was shown to replicate in 169 
pneumocytes, fibroblasts [23], as well as macrophages [24] cells lines in vitro, growth is very 170 
limited, in these cell lines, preventing accurate antibiotic susceptibility testing.  171 
Rifampicin was shown to be efficient against Parachlamydiaceae, similarly to what is 172 
observed for Chlamydia trachomatis. However, resistance are known to rapidly develop 173 
under treatment [25]. Therefore, caution should be taken when using this antibiotic in a single 174 
antibiotic regimen. 175 
Of utmost interest, our results confirm that unlike Chlamydia spp.[25–31], Neochlamydia and 176 
Parachlamydia spp. are resistant to quinolones, as already demonstrated for several other 177 
Chlamydia-related bacteria, including Simkania negevensis, Waddlia chondrophila and 178 
Estrella lausannensis [19,20,32]. This resistance is probably due to a mutation in the 179 
quinolones Resistance-Determining Region (QRDR) of gyrA, as shown by a recent 180 
publication [32]. Indeed, two substitutions were identified in quinolones resistant 181 
Chlamydiales when compared to susceptible Chlamydiaceae : (1) at position 70, the presence 182 
of a serine and (2) at position 83, the substitution of cysteine by another amino acid might 183 
induce resistance [32,33]. Quinolones such as levofloxacin represent one of the alternative 184 
treatments recommended for CAP, especially in patients that require in-treatment or patients 185 
suffering from additional co-morbidities in the objective to cover both S. pneumoniae and P. 186 
aeruginosa infection [34]. Since Chlamydia-related bacteria might represent 1-2% of 187 
community-acquired pneumonia, caution should be taken when prescribing quinolones.  188 
 189 
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FIGURES AND TABLE 333 
Figure 1: Growth kinetic of each parachlamydial strains in amoebae without antibiotic  334 
Kinetics were determined by quantitative PCR. Results are shown in a logarithmic scale as 335 
the means +/- standard deviation of triplicate experiments. 336 
 337 
Figure 2: Antibiotic susceptibility of each parachlamydial strains in amoebae 338 
Bacterial copy numbers were determined by quantitative PCR at day 3 post-infection, except 339 
when indicated by a *, where it was determined at day 4. Only results of significant 340 
experiments are shown. Results are shown in a logarithmic scale as the means +/- standard 341 
deviation in duplicate experiments. Abbreviations : Clari, clarithromycin; Ery, erythromycin; 342 
Doxy, doxycycline, Rifam, rifampicin; Amo, amoxicillin; Cef, ceftriaxone; Imi, imipenem; 343 
Cipro, ciprofloxacin; Oflo, ofloxacin.  344 
(A) Neochlamydia hartmanellae (B) Parachlamydia acanthamoebae strain Hall’s coccus (C) 345 
Parachlamydia acanthamoebae strain BN9 (D) Parachlamydia sp. Tumpl1 (E) Neochlamydia 346 
sp. UWC22. 347 
 348 
Table 1: Antibiotic susceptibility of Parachlamydiaceae and others Chlamydiales 349 
This table represents the MICs in µg/ml of various antibiotics against members of the 350 
Chlamydiales orders 351 
 352 
 353 
 354 
 355 


Table 1: Antibiotic susceptibility of Parachlamydiaceae  and others Chlamydiales
Parachlamydiaceae Waddliaceae Criblamydiaceae Chlamydiaceae
P. acanthamoebae N. hartmanellae Parachlamydiaceae spp. W. chondrophila E. lausannensis C. trachomatis C. pneumoniae
 BN9  BN9 Hall's coccus UWC22 Tumpl1
[17] [20] [19] [25-29] [29-31]
Cell lines Amoebae Vero Amoebae Vero Mc Coy, Hep2 HeLA
MIC (µl/ml)
Cyclines
Tetracycline 0.25 0.25-0.5 0.125-0.5
Doxycycline 0.5 4 2 4 ≥ 8 ≥ 8 0.25 1-4 0.25 0.06-0.25 0.015-0.5
Macrolides
Erythromycin 0.5 < 0.06 > 0.06 > 0.5 0.25 < 0.06 ND ND ND <0.125-2 <0.125-0.5
Clarithromycin 0.5 < 0.06 < 0.06 < 0.06 < 0.06 < 0.06 ND ND ND <0.125-2 <0.125-1
Azythromycin ND ND ND ND ND ND 0.25 0.006-0.125 2 <0.125-2 <0.125-0.5
β-lactams
Penicillin derivatives > 32 > 32 > 32 > 32 > 32 > 32 > 32 > 32 > 32 ND >100
Ceftriaxone > 32 > 32 > 32 > 32 > 32 > 32 > 32 > 32 > 32 <32 ND
Imipenem >32
Fluoroquinolones
Ciprofloxacin > 16 > 16 > 16 > 16 > 16 > 16 > 16 > 16 32 0.5-2 1-4
Ofloxacine > 16 > 16 > 16 > 16 > 16 > 16 > 16 > 16 16 0.5-1 0.5-2
Rifamycine
Rifampicine 0.25 0.25 0.5 1-2 0.25-0.5 0.25-0.5 ND ND ND <0.125-1 <0.125
Abbreviations : MIC, Minimal inhibitory concentration; ND, Not determined
